(URGN) UroGen Pharma - Ratings and Ratios
Jelmyto, UGN-102, UGN-103, UGN-104, RTGel
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 82.0% |
| Value at Risk 5%th | 104% |
| Relative Tail Risk | -23.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.06 |
| Alpha | 70.09 |
| CAGR/Max DD | 0.52 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.578 |
| Beta | 1.113 |
| Beta Downside | 1.179 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.64% |
| Mean DD | 31.71% |
| Median DD | 33.46% |
Description: URGN UroGen Pharma December 01, 2025
UroGen Pharma Ltd. (NASDAQ: URGN) is a U.S.-based biotech focused on developing and commercializing polymer-based drug delivery systems for urothelial and specialty cancers, leveraging its proprietary reverse-thermal gel (RTGel) platform.
The current pipeline centers on three late-stage candidates: UGN-102 (approved Jelmyto® for low-grade upper-tract urothelial carcinoma), UGN-103 (Phase 3 intravesical therapy for non-muscle-invasive bladder cancer, NMIBC) and UGN-104 (Phase 3 intrapelvic solution targeting low-grade NMIBC). Early-stage programs include UGN-301-based regimens (Phase 1) aimed at high-grade NMIBC.
UroGen has strategic collaborations that expand its commercial reach: a license with Agenus Inc. to co-develop intravesical products for urinary-tract cancers, and a development-supply agreement with medac GmbH for UGN-103 and UGN-104.
Key quantitative signals (as of Q2 2024) include a cash runway of roughly $120 million, a 27 % YoY increase in R&D spend reflecting intensified Phase 3 activity, and a market estimate of > $1.5 billion for NMIBC therapies in the United States-an area where polymer-based delivery could command premium pricing. The broader biotech sector continues to benefit from a 9 % annual growth in venture capital funding, supporting late-stage oncology innovators.
For a deeper, data-driven look at URGN’s valuation dynamics, you may find the analytics on ValueRay worth a quick scan.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-164.6m TTM) > 0 and > 6% of Revenue (6% = 5.79m TTM) |
| FCFTA -0.75 (>2.0%) and ΔFCFTA -42.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 130.9% (prev 293.5%; Δ -162.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.74 (>3.0%) and CFO -137.7m > Net Income -164.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (48.1m) change vs 12m ago 11.50% (target <= -2.0% for YES) |
| Gross Margin 87.95% (prev 90.27%; Δ -2.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.64% (prev 29.60%; Δ 10.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.36 (EBITDA TTM -130.7m / Interest Expense TTM 24.7m) >= 6 (WARN >= 3) |
Altman Z'' -18.88
| (A) 0.68 = (Total Current Assets 168.5m - Total Current Liabilities 42.2m) / Total Assets 185.0m |
| (B) -5.04 = Retained Earnings (Balance) -933.4m / Total Assets 185.0m |
| warn (B) unusual magnitude: -5.04 — check mapping/units |
| (C) -0.54 = EBIT TTM -132.5m / Avg Total Assets 243.5m |
| (D) -3.11 = Book Value of Equity -933.2m / Total Liabilities 300.5m |
| Total Rating: -18.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.48
| 1. Piotroski 1.0pt |
| 2. FCF Yield -12.09% |
| 3. FCF Margin data missing |
| 4. Debt/Equity -1.13 |
| 5. Debt/Ebitda -0.31 |
| 7. RoE 249.4% |
| 8. Rev. Trend 87.46% |
| 9. EPS Trend 68.40% |
What is the price of URGN shares?
Over the past week, the price has changed by -20.24%, over one month by +19.01%, over three months by +21.72% and over the past year by +88.21%.
Is URGN a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the URGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.3 | 53.4% |
| Analysts Target Price | 35.3 | 53.4% |
| ValueRay Target Price | 26.2 | 14.1% |
URGN Fundamental Data Overview December 05, 2025
P/S = 11.8094
P/B = 19.2691
Beta = 1.261
Revenue TTM = 96.5m USD
EBIT TTM = -132.5m USD
EBITDA TTM = -130.7m USD
Long Term Debt = 122.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.59m USD (from shortTermDebt, last quarter)
Debt = 129.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.14b USD (1.14b + Debt 129.9m - CCE 127.0m)
Interest Coverage Ratio = -5.36 (Ebit TTM -132.5m / Interest Expense TTM 24.7m)
FCF Yield = -12.09% (FCF TTM -138.1m / Enterprise Value 1.14b)
FCF Margin = -143.1% (FCF TTM -138.1m / Revenue TTM 96.5m)
Net Margin = -170.6% (Net Income TTM -164.6m / Revenue TTM 96.5m)
Gross Margin = 87.95% ((Revenue TTM 96.5m - Cost of Revenue TTM 11.6m) / Revenue TTM)
Gross Margin QoQ = 88.07% (prev 85.34%)
Tobins Q-Ratio = 6.18 (Enterprise Value 1.14b / Total Assets 185.0m)
Interest Expense / Debt = 6.15% (Interest Expense 7.99m / Debt 129.9m)
Taxrate = 3.06% (-1.05m / -34.4m)
NOPAT = -128.4m (EBIT -132.5m * (1 - 3.06%)) [loss with tax shield]
Current Ratio = 3.99 (Total Current Assets 168.5m / Total Current Liabilities 42.2m)
Debt / Equity = -1.13 (negative equity) (Debt 129.9m / totalStockholderEquity, last quarter -115.4m)
Debt / EBITDA = -0.31 (negative EBITDA) (Net Debt 39.9m / EBITDA -130.7m)
Debt / FCF = -0.29 (negative FCF - burning cash) (Net Debt 39.9m / FCF TTM -138.1m)
Total Stockholder Equity = -66.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -88.97% (Net Income -164.6m / Total Assets 185.0m)
RoE = 249.4% (negative equity) (Net Income TTM -164.6m / Total Stockholder Equity -66.0m)
RoCE = -236.2% (out of range, set to none) (EBIT -132.5m / Capital Employed (Equity -66.0m + L.T.Debt 122.1m))
RoIC = -197.3% (out of range, set to none) (NOPAT -128.4m / Invested Capital 65.1m)
WACC = 9.69% (E(1.14b)/V(1.27b) * Re(10.12%) + D(129.9m)/V(1.27b) * Rd(6.15%) * (1-Tc(0.03)))
Discount Rate = 10.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.29%
Fair Price DCF = unknown (Cash Flow -138.1m)
EPS Correlation: 68.40 | EPS CAGR: 57.26% | SUE: -0.29 | # QB: 0
Revenue Correlation: 87.46 | Revenue CAGR: 15.18% | SUE: -2.99 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.51 | Chg30d=+0.047 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.60 | Chg30d=+0.726 | Revisions Net=-1 | Growth EPS=+80.8% | Growth Revenue=+123.0%
Additional Sources for URGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle